Johnson & Johnson
JNJ: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$338.00 | Ylh | Pmwdzzxn |
Johnson & Johnson Earnings: Largely in Line as New Products Ready to Offset Stelara Biosimilars
We are holding our Johnson Johnson fair value estimate steady at $164 per share following second-quarter results that largely ran in line with our expectations. The stock looks undervalued, with the market likely not fully appreciating the broad innovation across the firm's pipeline that should drive steady growth and reinforce JJ's wide moat.